Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
79.99
-10.45 (-11.55%)
At close: Dec 5, 2025, 4:00 PM EST
80.02
+0.03 (0.04%)
After-hours: Dec 5, 2025, 7:43 PM EST
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $697.00K in the twelve months ending September 30, 2025, down -90.18% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
$697.00K
Revenue Growth
-90.18%
P/S Ratio
66.62
Revenue / Employee
$33,190
Employees
21
Market Cap
85.62M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRB News
- 25 days ago - Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 2 months ago - Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade) - Seeking Alpha
- 2 months ago - This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug. - Barrons
- 2 months ago - Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 2 months ago - Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - Business Wire